CIK 0001906324
- Large accelerated filer
QuidelOrtho Corp
Sign in to watch- Ticker
- QDEL
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Jan 1
- Entity type
- Operating
- EIN
- 874496285
- Phone
- +1 858-552-1100
- Business address
- 9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA, 92121
- Former names
- Coronado Topco, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-28 | Busky Joseph M Chief Financial Officer | Grant or award · Restricted Stock Units | +14,775 | 14,775 | ||
| 2023-03-28 | Bujarski Robert Joseph EVP & COO | Grant or award · Non-Qualified Stock Option | +14,775 | 14,775 | ||
| 2023-03-28 | Bujarski Robert Joseph EVP & COO | Grant or award · Restricted Stock Units | +14,775 | 14,775 | ||
| 2023-03-28 | BRYANT DOUGLAS C President & CEO | Grant or award · Non-Qualified Stock Option | +31,027 | 31,027 | ||
| 2023-03-28 | BRYANT DOUGLAS C President & CEO | Grant or award · Restricted Stock Units | +31,028 | 31,028 | ||
| 2023-02-28 | BRYANT DOUGLAS C President & CEO | Grant or award · Restricted Stock Units (Converted) | +10,656 | 10,656 | ||
| 2023-02-28 | BRYANT DOUGLAS C President & CEO | Grant or award · Restricted Stock Units (Premium) | +3,273 | 3,273 | ||
| 2023-02-23 | BRYANT DOUGLAS C President & CEO | Grant or award | +15,180 | 542,070 | ||
| 2023-02-23 | BRYANT DOUGLAS C President & CEO | Shares withheld for taxes | −7,527 | $88.71 | $668K | 534,543 |
| 2023-02-17 | BUECHLER KENNETH F Director | Exercise or conversion | +8,081 | $23.70 | $192K | 78,369 |
| 2023-02-17 | BUECHLER KENNETH F Director | Sale | −8,081 | $90.26 | $729K | 70,288 |
| 2023-02-17 | BUECHLER KENNETH F Director | Exercise or conversion · Non-Qualified Stock Options | −8,081 | 0 | ||
| 2023-02-11 | Kroll Werner SVP, Research & Development | Grant or award | +2,743 | 29,137 | ||
| 2023-02-11 | Kroll Werner SVP, Research & Development | Shares withheld for taxes | −1,296 | $86.50 | $112K | 27,841 |
| 2023-02-11 | Kroll Werner SVP, Research & Development | Grant or award | +823 | 28,664 | ||
| 2023-02-11 | Kroll Werner SVP, Research & Development | Shares withheld for taxes | −409 | $86.50 | $35K | 28,255 |
| 2023-02-11 | Kroll Werner SVP, Research & Development | Exercise or conversion · Restricted Stock Units (Converted) | −2,743 | 0 | ||
| 2023-02-11 | Kroll Werner SVP, Research & Development | Exercise or conversion · Restricted Stock Units (Premium) | −823 | 0 | ||
| 2023-02-11 | Bujarski Robert Joseph EVP & COO | Grant or award | +2,749 | 37,103 | ||
| 2023-02-11 | Bujarski Robert Joseph EVP & COO | Shares withheld for taxes | −1,381 | $86.50 | $119K | 35,722 |
Page 37 of 50 · 990 trades